Register by Jan 13 to save on passes and connect with marketers from Uber, Bose and more
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
OpenAI’s countdown: monetization, ads, and a Google-shaped threat
With fierce competition from Google et al, the clock is ticking for the AI company to launch its ad business.
Crisis, culture and costs: The new reality of the modern CMO
Crisis, culture and cost pressures are reshaping the modern CMO into a revenue-driven strategist uniting marketing, communications and finance.
Digiday+ Research: The marketer’s guide to AI applications, agentic AI, AI search and GEO/AEO in 2026
Digiday’s annual AI report explores how marketers are navigating the opportunities and challenges AI brings as it becomes an indispensable piece in their toolkits.